First Wave BioPharma Inc. (FWBI) Financial Statements (2025 and earlier)

Company Profile

Business Address 777 YAMATO ROAD
BOCA RATON, FL 33431
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments662,4793,431,9133,711,7703,292,3271,236,0542,064,435
Cash and cash equivalents662,4793,431,9133,711,7703,292,3271,236,0542,064,435
Restricted cash and investments 20,000     
Receivables      20,000
Prepaid expense554,4454,058,0531,244,466684,2731,117,7371,445,438
Disposal group, including discontinued operation83,170,009     
Other undisclosed current assets (20,000)     
Total current assets:84,386,9337,489,9664,956,2363,976,6002,353,7913,529,873
Noncurrent Assets
Operating lease, right-of-use asset161,737181,421195,440211,832227,927243,733
Property, plant and equipment 1,33525,74914,56521,88429,20236,521
Intangible assets, net (including goodwill)2,022,58483,403,9941,684,1821,684,1821,684,1821,684,182
Goodwill1,684,18220,038,5081,684,1821,684,1821,684,1821,684,182
Intangible assets, net (excluding goodwill) 338,40263,365,486    
Deposits noncurrent assets31,75011,25011,25011,25011,25018,149
Other undisclosed noncurrent assets(316,886)21,52221,52221,52121,51921,518
Total noncurrent assets:1,900,52083,643,9361,926,9591,950,6691,974,0802,004,103
TOTAL ASSETS:86,287,45391,133,9026,883,1955,927,2694,327,8715,533,976
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,836,5224,550,9651,379,5671,413,8312,071,0571,315,488
Accounts payable2,014,0491,996,519554,277579,2911,591,195469,760
Accrued liabilities1,822,4732,554,446825,290834,540479,862845,728
Debt 177,563386,769612,784 153,478380,390
Disposal group, including discontinued operation10,110,414     
Other liabilities 8,97428,5464,23910,80629,90712,123
Other undisclosed current liabilities1,251,2501,206,9761,136,7271,057,8571,006,807916,855
Total current liabilities:15,384,7236,173,2563,133,3172,482,4943,261,2492,624,856
Noncurrent Liabilities
Long-term debt and lease obligation  6,397,889    
Long-term debt, excluding current maturities  6,397,889    
Liabilities, other than long-term debt101,035698,813146,949165,970184,662196,524
Deferred income tax liabilities  571,221    
Operating lease, liability101,035127,592146,949165,970184,662196,524
Total noncurrent liabilities:101,0357,096,702146,949165,970184,662196,524
Total liabilities:15,485,75813,269,9583,280,2662,648,4643,445,9112,821,380
Temporary equity, carrying amount61,681,10061,681,100    
Equity
Equity, attributable to parent9,120,59516,182,8443,602,9293,278,805881,9602,712,596
Common stock2942031561,346421155
Additional paid in capital196,689,069194,943,707187,931,445183,505,191177,675,113175,316,783
Accumulated deficit(187,568,768)(178,761,066)(184,328,672)(180,227,732)(176,793,574)(172,604,342)
Total equity:9,120,59516,182,8443,602,9293,278,805881,9602,712,596
TOTAL LIABILITIES AND EQUITY:86,287,45391,133,9026,883,1955,927,2694,327,8715,533,976

Income Statement (P&L) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Operating expenses(3,426,108)(9,225,654)(4,093,621)(3,433,137)(4,181,644)(4,062,425)
Operating loss:(3,426,108)(9,225,654)(4,093,621)(3,433,137)(4,181,644)(4,062,425)
Nonoperating expense(4,114)(66,627)(7,319)(1,021)(7,588)(8,228)
Investment income, nonoperating  2282242292051,873
Other nonoperating expense(4,332)(653)(495) (2,615)(1,114)
Interest and debt expense218(66,202)(7,048)(1,250)(5,178)(8,987)
Loss from continuing operations before equity method investments, income taxes:(3,430,004)(9,358,483)(4,107,988)(3,435,408)(4,194,410)(4,079,640)
Other undisclosed income (loss) from continuing operations before income taxes(218)66,202    
Loss from continuing operations before income taxes:(3,430,222)(9,292,281)(4,107,988)(3,435,408)(4,194,410)(4,079,640)
Income tax expense (benefit) (4,255,247)14,859,887    
Net income (loss):(7,685,469)5,567,606(4,107,988)(3,435,408)(4,194,410)(4,079,640)
Other undisclosed net income (loss) attributable to parent(1,122,233) 7,0481,2505,1788,987
Net income (loss) attributable to parent:(8,807,702)5,567,606(4,100,940)(3,434,158)(4,189,232)(4,070,653)
Preferred stock dividends and other adjustments(38,058)(66,144)(77,081)(49,292)(94,324)(87,431)
Net income (loss) available to common stockholders, basic:(8,845,760)5,501,462(4,178,021)(3,483,450)(4,283,556)(4,158,084)
Other undisclosed net income available to common stockholders, diluted  66,144    
Net income (loss) available to common stockholders, diluted:(8,845,760)5,567,606(4,178,021)(3,483,450)(4,283,556)(4,158,084)

Comprehensive Income (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net income (loss):(7,685,469)5,567,606(4,107,988)(3,435,408)(4,194,410)(4,079,640)
Comprehensive income (loss):(7,685,469)5,567,606(4,107,988)(3,435,408)(4,194,410)(4,079,640)
Other undisclosed comprehensive income, net of tax, attributable to parent   7,0481,2505,1788,987
Comprehensive income (loss), net of tax, attributable to parent:(7,685,469)5,567,606(4,100,940)(3,434,158)(4,189,232)(4,070,653)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: